Piramal set to sell bioequivalence CRO business to Indoco

By Dan Stanton contact

- Last updated on GMT

Related tags: Clinical research

Indoco set to add BE/BA services through acquisition of Piramal Clinical Research
Indoco set to add BE/BA services through acquisition of Piramal Clinical Research
Piramal has agreed to sell its clinical research business based in Hyderabad, India to Indoco Remedies which will add bio-equivalence and bio-analytical services to its offerings.

Indoco signed a definitive agreement to acquire Piramal Clinical Research (PCR) yesterday, and will be able to offer its customers a number of new services on top of its current API and finished dosage development and manufacturing.

The new acquisition of CRO will fit with Indoco’s current service offering perfectly as it will now be able to offer complete solution to its generic customers including the bio-equivalence (BE) and bio analytical (BA) studies,”​ Indoco spokesperson Kailash Rajwadkar told Outsourcing-Pharma.com.

He added there is no overlap in the current activities at Indoco, and the business will operate as a separate division under the name of Anacipher.

“The CRO will offer services on captive basis to Indoco and also to external customers. The operational integration will be smooth and on a broad scale allowing the CRO to operate as an independent division. But there will be no cross over and there will be no job cuts.”

He continued: “The acquisition was driven by general demand as well as difficulties faced by us in terms of delays and costs while outsourcing BE BA studies.”

Indoco had been outsourcing its BE/BA studies, and some of these will now be transferred through the new division Anacipher.

Financial details of the deal have not been divulged, but Akansha Pradhan – a spokesperson from Piramal – said the transaction has no material impact on Piramal’s balance sheet or P&L.

“PCR was not considered strategic in PEL’s contract services and manufacturing business and formed a relatively small portion of the PEL’s consolidated business,”​ she told us.

She added: “Customers should not be affected given that only ownership has changed and the assets and employees have been transferred on a going concern basis as a part of the transaction.”

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars